Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22181851 | 0.74 | CYP1A2 (0.56) | TNIKHRH3LIMK1 | |
| SCHEMBL22181977 | 0.74 | TNIK (0.43) | TNIKMAPTEDNRALIMK1NR1I2 | |
| SCHEMBL22080186 | 0.74 | TP53 (0.44) | CA9 | |
| SCHEMBL22182004 | 0.73 | TNIK (0.39) | TNIKMAPTEDNRALIMK1NR1I2 | |
| SCHEMBL1924747 | 0.72 | MAPT (0.57) | TNIKMAPTEDNRANR1I2AHR | |
| SCHEMBL11052435 | 0.69 | NPC1 (0.49) | MAPT | |
| SCHEMBL22181839 | 0.69 | TNIK (0.39) | TNIKMAPTLIMK1CHRNA7AR | |
| SCHEMBL22182001 | 0.68 | LIMK1 (0.54) | TNIKMAPTLIMK1 | |
| SCHEMBL2492357 | 0.67 | MAPT (0.67) | TNIKHRH3MAPTHTTGAA | |
| SCHEMBL8260133 | 0.67 | ALDH1A1 (0.48) | MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143005-A1 | NAPHTHALIMIDE DERIVATIVES AS ANTI-PARASITIC AGENTS FOR THE TREATMENT OF LEISHMANIASIS AS WELL AS VIRAL, BACTERIAL AND NEOPLASTIC DISEASES | ISTANBUL MEDIPOL UNIVERSITESI (TR) | 2022-05-12 | — | — | US | disclosed |
| WO-2020139291-A1 | NAPHTHALIMIDE DERIVATIVES AS ANTI-PARASITIC AGENTS FOR THE TREATMENT OF LEISHMANIASIS AS WELL AS VIRAL, BACTERIAL AND NEOPLASTIC DISEASES | ISTANBUL MEDIPOL UNIVERSITESI (TR) | 2020-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143005-A1 | NAPHTHALIMIDE DERIVATIVES AS ANTI-PARASITIC AGENTS FOR THE TREATMENT OF LEISHMANIASIS AS WELL AS VIRAL, BACTERIAL AND NEOPLASTIC DISEASES | NPM1, ECI1, IPO5 | TNIK 1979/4885HRH3 923/4885MAPT 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.